期刊文献+

唑来膦酸与化疗联合治疗多发性骨髓瘤骨痛的疗效观察 被引量:5

下载PDF
导出
摘要 目的观察唑来膦酸与化疗联合治疗多发性骨髓瘤(multiple myeloma,MM)骨病的临床疗效和安全性。方法入选确诊的MM46例,随机分为两组,各23例。对照组单纯VAD(长春新碱+阿霉素+地塞米松)方案化疗,联合化疗组加用唑来膦酸联合VAD方案,3个疗程后比较患者骨疼改善效果,评价其疗效并检查骨X线或骨ECT观察骨病灶范围减少状况。结果联合组23例患者经过治疗骨痛得到不同程度的缓解,其中显效8例,有效12例,无效3例,有效率86.96%,明显高于对照组,差异有统计学意义(P<0.05)。联合化疗组通过影像学检查证实有9例见新骨形成,原骨病灶范围不同程度缩小。联合化疗组中血钙浓度较治疗前下降,无高钙血症发生。结论唑来膦酸治疗多发性骨髓瘤骨痛疗效确切,不良反应小,值得临床应用。
作者 涂刚
出处 《当代医学》 2013年第17期148-149,共2页 Contemporary Medicine
  • 相关文献

参考文献8

二级参考文献74

  • 1Jemal A, Siegel R, Ward E, et al. Cancer statistics 2007 [ J ]. CA Cancer J Clin, 2007, 57: 43-60.
  • 2Sirohi B, Powles R. Multiple myeloma[ J ]. Lancet, 2004, 363 : 875 - 887.
  • 3Kozuru M, Uike N, Takahira H, et al. Immunoglobulin class switch from IgA1 to IgG2 and simultaneous a,sociation with Bence Jones proteinuria in the escape phase in a myeloma patient treated with interferon alpha[ J ]. Br J Haematol, 1997,98 : 114-118.
  • 4Bartl R, Frisch B. Clinical significance of bone marrow biopsy and plasma cell morphology in MM and MGUS[J]. Pathologie Biologie, 1999, 47 : 158-168.
  • 5San Miguel JF, Almeida J, Mateo G, et al. Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome[ J]. Blood, 2002,99 : 1853-1856.
  • 6Paiva B, Vidfiales MB, Cervero J, et al. Multiparameter flow cytometry remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation [J]. Blood, 2008, 112: 4017-4023.
  • 7Dispenzieri A, Zhang L, Katzmann JA, et al. Appraisal of immunoglobulin free light chain as a marker of response [ J]. Blood, 2008,111:4908-4915.
  • 8Dispenzieri A, Lacy MQ, Katzmann JA, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation[ J]. Blood, 2006,107:3378-3383.
  • 9Shaw GR. Nonsecretory plasma cell myeloma-becoming even more rare with serum flee light-chain assay: a brief review [ J ]. Arch Pathol Lab Med, 2006, 130:1212-1215.
  • 10van Rhee F, Bolejack V, Hollmig K, et al. High serum free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis [ J ]. Blood, 2007,110:827- 832.

共引文献21

同被引文献60

  • 1史春雷,王玲,尹刚,袁成录.唑来膦酸联合化疗对多发性骨髓瘤病人骨痛的治疗效果[J].齐鲁医学杂志,2006,21(1):41-42. 被引量:4
  • 2蒋铁斌,李昕,刘竞,肖广芬.唑来膦酸钠联合化疗治疗多发性骨髓瘤疗效观察[J].广东医学,2007,28(3):443-443. 被引量:2
  • 3宋燕萍.骨髓瘤骨病发病机制及诊治的研究进展.国际输血及血液学杂志,2008,31(2):174-177.
  • 4张之南,沈悌.血液病诊断及疗效标准[M].北京:科学出版社,2008.103-122,131-134,172-176.
  • 5Kim HJ,Yoon SS,Lee DS,et al.Sequential vincristine,adriamycin,dexamethasone(VAD)followed by bortezomib,thalidomide,dexamethasone(VTD)as induction,followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma:Results of a phase II trial [J].Ann Hematol,2012,91(2):249-259.
  • 6Green JR,Guenther A.The backbone of progress-preclinical studies and innovations with zoledronic acid [J].Crit Rev Oncol Hematol,2011,77(Suppl 1):S3-S12.
  • 7Morgan G,Child J,Gregory W,et al.Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma(MRC Myeloma IX):Secondary outcomes from a randomized controlled trial[J].Lancet Oncol,2011,12(8):743-752.
  • 8Major P,Lortholary A,Hon J,et al.Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy:A pooled analysis of two randomizd,controlled clinical trials[J].J Clin Oncol,2001,19(2):558.
  • 9Kyle R A, Rajkumar S V. Multiple myel0ma[J]. N Engl J Med, 2004, 351(18): 1860-1873.
  • 10Anderson K C, Alsina M, Bensinger W, et al. NCCN clini-cal practice guidelines in oncology: multiple myeloma[J]. J Natl Compr Canc Netw, 2009, 7(9): 908-942.

引证文献5

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部